drugset
drugset / Trial / NCT01376323

A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

NCT01376323 ↗

Phase 2 Completed 92 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this combined, two part study is to evaluate the safety and glucose lowering effects of GSK256073 when administered to diabetic subjects for 12 weeks.

Timeline

Start
2011-07-13
Primary completion
2012-09-16
Completion
2012-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK256073 Unknown 1 mg Oral
Subject GSK256073 Unknown 2 mg Oral
Subject GSK256073 Unknown 5 mg Oral
Subject GSK256073 Unknown 10 mg Oral
Subject GSK256073 Unknown 20 mg Oral
Subject GSK256073 Unknown 25 mg Oral
Subject GSK256073 Unknown 50 mg Oral
Comparator Sitagliptin Small molecule 100 mg Oral

Indications

type 2 diabetes mellitus